ClinicalTrials.gov
public full text
Public Domain
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC#140986
- Efficacy of Ultrasound Guided Microwave Ablation in the Treatment of Uterine Fibroids.#835562
- Comparison of Microwave Ablation With Breast Conserving Surgery for Breast Tumor#861528
- The immunological fitness of NSCLC patients drives the response to anti-PD1-based immunotherapy regardless of age#652989
- Comparison of Microwave Ablation With Cryoablation for Breast Tumor#861166
Record · ID 136302
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive